Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940223 · ClinicalTrials.gov registry record · Phase 2
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02940223: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02940223 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02940223, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body. Ethyl icosapentate and physical activity may provide more robust and clinically effective improvement of cancer related fatigue, which may facilitate patients continuing cancer therapy since it would be tolerated and effective in controlling disease.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- BEHAVIORAL Exercise Intervention
- DRUG Ethyl Icosapentate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-03-16 |
| Est. Completion | 2020-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02940223
The ClinicalTrials.gov registry entry for NCT02940223 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02940223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02940223 about?
NCT02940223 is a clinical study titled "Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer". This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body. Ethyl icosapentate and physical activity may provide more robust and clinically effective impro...
What is the current status of trial NCT02940223?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-03-16. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT02940223?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Exercise Intervention (BEHAVIORAL), Ethyl Icosapentate (DRUG).
Who is sponsoring clinical trial NCT02940223?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.